Expert opinion on investigational drugs最新文献_第7页

Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status. 用于治疗南美锥虫病的临床前和早期临床开发药物：现状。

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-06-01 Epub Date: 2024-05-14 DOI: 10.1080/13543784.2024.2349289

Fernanda Karoline Vieira da Silva Torchelsen, Ana Lia Mazzeti, Vanessa Carla Furtado Mosqueira

{"title":"Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status.","authors":"Fernanda Karoline Vieira da Silva Torchelsen, Ana Lia Mazzeti, Vanessa Carla Furtado Mosqueira","doi":"10.1080/13543784.2024.2349289","DOIUrl":"10.1080/13543784.2024.2349289","url":null,"abstract":"Introduction: Chagas disease is spreading faster than expected in different countries, and little progress has been reported in the discovery of new drugs to combat Trypanosoma cruzi infection in humans. Recent clinical trials have ended with small hope. The pathophysiology of this neglected disease and the genetic diversity of parasites are exceptionally complex. The only two drugs available to treat patients are far from being safe, and their efficacy in the chronic phase is still unsatisfactory.Areas covered: This review offers a comprehensive examination and critical review of data reported in the last 10 years, and it is focused on findings of clinical trials and data acquired in vivo in preclinical studies.Expert opinion: The in vivo investigations classically in mice and dog models are also challenging and time-consuming to attest cure for infection. Poorly standardized protocols, availability of diagnosis methods and disease progression markers, the use of different T. cruzi strains with variable benznidazole sensitivities, and animals in different acute and chronic phases of infection contribute to it. More synchronized efforts between research groups in this field are required to put in evidence new promising substances, drug combinations, repurposing strategies, and new pharmaceutical formulations to impact the therapy.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"575-590"},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy. 表皮生长因子受体拮抗剂在结直肠癌中的应用：精准治疗的新策略。

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-06-01 Epub Date: 2024-05-22 DOI: 10.1080/13543784.2024.2349287

Nadia Saoudi González, Paola Valeria Marchese, Iosune Baraibar, Javier Ros, Francesc Salvà, Marta Rodríguez, Clara Salvà, Caterina Vaghi, Adriana Alcaraz, Ariadna García, Josep Tabernero, Elena Élez

{"title":"Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy.","authors":"Nadia Saoudi González, Paola Valeria Marchese, Iosune Baraibar, Javier Ros, Francesc Salvà, Marta Rodríguez, Clara Salvà, Caterina Vaghi, Adriana Alcaraz, Ariadna García, Josep Tabernero, Elena Élez","doi":"10.1080/13543784.2024.2349287","DOIUrl":"10.1080/13543784.2024.2349287","url":null,"abstract":"Introduction: The global prevalence of colorectal cancer highlights the need to enhance treatment strategies for improved patient outcomes. The pivotal role of epidermal growth factor receptor (EGFR) signaling in regulating cellular processes for this disease pinpoints its value as a therapeutic target, despite the emergence of resistance mechanisms over time.Areas covered: This review discusses the clinical evidence supporting the use of EGFR inhibitors in molecularly-selected patients based on molecular characteristics (notably BRAF V600E and KRAS G12C) including combination approaches targeting different points in in the signaling pathway, as well as strategies such as EGFR inhibitor rechallenge. The role of HER2 inhibitors and emerging approaches such as bispecific antibodies are also reviewed.Expert opinion: Recently, inhibitors targeting the KRAS G12C variant have emerged, albeit with modest monotherapy activity compared to other tumor types, emphasizing the influence of histologic origins on the EGFR signaling pathway. Integration of EGFR inhibitors into precision medicine has facilitated tailored therapies addressing resistance mechanisms. Patient selection for EGFR inhibitor rechallenge guided by ctDNA findings is crucial, with ongoing investigations exploring novel combinations to enhance EGFR blockade, highlighting the transformative potential of precision medicine in shaping the future of mCRC treatment toward personalized and targeted approaches.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"613-625"},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141075940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis? 从工作台到床边--IL-17 药物在类风湿性关节炎中能发挥作用吗？

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-06-01 Epub Date: 2024-05-09 DOI: 10.1080/13543784.2024.2351505

Swetha Byravan, Harini Samarasinghe, Jack Shi Jie Yuan, Syed Haider Tahir, Arumugam Moorthy, Hasan Tahir

{"title":"From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?","authors":"Swetha Byravan, Harini Samarasinghe, Jack Shi Jie Yuan, Syed Haider Tahir, Arumugam Moorthy, Hasan Tahir","doi":"10.1080/13543784.2024.2351505","DOIUrl":"10.1080/13543784.2024.2351505","url":null,"abstract":"Introduction: IL-17 has been described as a pro-inflammatory cytokine that is relevant in the seronegative spondylarthritides with IL-17 targeted therapies being licensed for their treatment.There is evidence to demonstrate that IL-17 is found in RA joints and contributes to the pro-inflammatory cascade. This results in synovial hyperplasia and osteoclastogenesis thus causing joint destruction and bony erosions.Areas covered: This review article summarizes trials that have studied the use of IL-17 targeted therapies in RA patients who have failed conventional synthetic disease-modifying therapy (C-DMARDS) and biologic DMARDS.Expert opinion: The trials that have studied IL-17 inhibitors in RA patients have only shown a modest improvement in disease activity. In several trials, the primary endpoint was not achieved whilst in others, when comparing with existing licensed biologics for RA, did not demonstrate any superiority.Tissue Necrosis Factor-alpha (TNF-α) likely plays more of a pivotal role in the pathogenesis of RA with IL-17 having a synergistic effect. Therefore, in our opinion, IL-17 inhibitors as an independent therapy for RA are less likely to provide a cost-effective benefit. There may be scope to potentially combine it with TNF-α-inhibitors (TNF-i), but this requires further research especially with the potential concerns related to increased immunosuppression.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"591-600"},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection. 治疗幽门螺旋杆菌感染的新型碳酸酐酶抑制剂。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-05-01 Epub Date: 2024-03-27 DOI: 10.1080/13543784.2024.2334714

Claudiu T Supuran

{"title":"Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection.","authors":"Claudiu T Supuran","doi":"10.1080/13543784.2024.2334714","DOIUrl":"10.1080/13543784.2024.2334714","url":null,"abstract":"Introduction: Helicobacter pylori, the causative agent of peptic ulcer, gastritis, and gastric cancer encodes two carbonic anhydrases (CA, EC 4.2.1.1) belonging to the α- and β-class (HpCAα/β), which have been validated as antibacterial drug targets. Acetazolamide and ethoxzolamide were also clinically used for the management of peptic ulcer.Areas covered: Sulfonamides were the most investigated HpCAα/β compounds, with several low nanomolar inhibitors identified, some of which also crystallized as adducts with HpCAα, allowing for the rationalization of the structure-activity relationship. Few data are available for other classes of inhibitors, such as phenols, sulfamides, sulfamates, dithiocarbamates, arylboronic acids, some of which showed effective in vitro inhibition and for phenols, also inhibition of planktonic growth, biofilm formation, and outer membrane vesicles spawning.Expert opinion: Several recent drug design studies reported selenazoles incorporating seleno/telluro-ethers attached to benzenesulfonamides, hybrids incorporating the EGFR inhibitor erlotinib and benzenesulfonamides, showing KIs < 100 nM against HpCAα and MICs in the range of 8-16 µg/mL for the most active derivatives. Few drug design studies for non-sulfonamide inhibitors were performed to date, although inhibition of these enzymes may help the fight of multidrug resistance to classical antibiotics which emerged in the last decades also for this bacterium.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"523-532"},"PeriodicalIF":6.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140189625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inflammation and Huntington's disease - a neglected therapeutic target? 炎症与亨廷顿氏病--一个被忽视的治疗靶点？

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-05-01 Epub Date: 2024-05-29 DOI: 10.1080/13543784.2024.2348738

Sophie E Field, Annabel J Curle, Roger A Barker

{"title":"Inflammation and Huntington's disease - a neglected therapeutic target?","authors":"Sophie E Field, Annabel J Curle, Roger A Barker","doi":"10.1080/13543784.2024.2348738","DOIUrl":"10.1080/13543784.2024.2348738","url":null,"abstract":"Introduction: Huntington's Disease (HD) is a genetic neurodegenerative disease for which there is currently no disease-modifying treatment. One of several underlying mechanisms proposed to be involved in HD pathogenesis is inflammation; there is now accumulating evidence that the immune system may play an integral role in disease pathology and progression. As such, modulation of the immune system could be a potential therapeutic target for HD.Areas covered: To date, the number of trials targeting immune aspects of HD has been limited. However, targeting it, may have great advantages over other therapeutic areas, given that many drugs already exist that have actions in this system coupled to the fact that inflammation can be measured both peripherally and, to some extent, centrally using CSF and PET imaging. In this review, we look at evidence that the immune system and the newly emerging area of the microbiome are altered in HD patients, and then present and discuss clinical trials that have targeted different parts of the immune system.Expert opinion: We then conclude by discussing how this field might develop going forward, focusing on the role of imaging and other biomarkers to monitor central immune activation and response to novel treatments in HD.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"451-467"},"PeriodicalIF":6.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140957184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus. PAISLEY 研究的通俗摘要：将 deucravacitinib 作为系统性红斑狼疮患者的一种治疗方法。

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-05-01 Epub Date: 2024-05-29 DOI: 10.1080/13543784.2024.2337736

Eric F Morand, Marilyn Pike, J Merrill, Ronald F van Vollenhoven, Victoria P Werth, Coburn Hobar, Nikolay Delev, Vaishali Shah, Brian Sharkey, Thomas Wegman, Ian Catlett, Subhashis Banerjee, Shalabh Singhal

引用次数: 0

Novel investigational drugs for alopecia areata and future perspectives 治疗斑秃的新型研究药物及未来展望

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-29 DOI: 10.1080/13543784.2024.2348062

Ivana Chim, Ragini Ghiya, Rodney D Sinclair, Samantha Eisman

引用次数: 0

Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis 治疗原发性胆汁性胆管炎的研究性法尼类固醇 X 受体激动剂

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-27 DOI: 10.1080/13543784.2024.2348743

Prithvi Reddy Akepati, Eric M Gochanour

引用次数: 0

Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind phase I study in healthy subjects 新型 RdRp 抑制剂 SHEN26 对抗 SARS-CoV-2 的安全性、耐受性和药代动力学：一项针对健康受试者的随机、安慰剂对照、双盲 I 期研究

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-25 DOI: 10.1080/13543784.2024.2347302

Cheng Sun, Hao Liu, Ziwei Ouyang, Jie Ding, Qin Zhang, Hongjie Ma, Dandan Xu, Qian Zhang, Renpeng Zhou, Mingming Yang, Wei Hu

引用次数: 0

Experimental and new investigational drugs for the treatment of uterine fibroids 治疗子宫肌瘤的试验性药物和新研究药物

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-15 DOI: 10.1080/13543784.2024.2343786

Giulio Evangelisti, Simone Ferrero, Umberto Perrone, Claudio Gustavino, Eugenio Volpi, Alberto Izzotti, Fabio Barra

引用次数: 0